Guérard F, Navarro L, Lee Y-S, Roumesy A, Alliot C, Chérel M, Brechbiel M W, Gestin J-F
CRCINA, Inserm, CNRS, Université d'Angers, Université de Nantes, Nantes, France.
CRCINA, Inserm, CNRS, Université d'Angers, Université de Nantes, Nantes, France.
Bioorg Med Chem. 2017 Nov 1;25(21):5975-5980. doi: 10.1016/j.bmc.2017.09.022. Epub 2017 Sep 19.
In this report we describe the development of an alternative approach to arylstannane chemistry for radiolabeling antibodies with radioiodine or astatine based on aryliodonium salts precursors. Bifunctional aryliodonium salts were designed and tested for the synthesis of I and At labeled prosthetic groups for bioconjugation. The nature of the electron rich aryl group was varied and its impact on the regioselectivity of radiohalogenation was evaluated. Unexpectedly, whereas the 2-thienyl group provided the best regioselectivity towards the radioiodination of the aryl moiety of interest (98:2), it was less selective for astatination (87:13); the anisyl group providing the best regioselectivity of astatination (94:6). Under optimized conditions, both radioiodination and astatination could be performed very efficiently in mild conditions (radiochemical yields>85%). The ionic nature of the precursors was exploited to develop an efficient purification approach: the HPLC step that is usually necessary in conventionnal approaches to optimize removal of organotin toxic precursors and side products was replaced by a filtration through a silica cartridge with a significantly reduced loss of radiolabeled product. The purified radioiodinated and astatinated prosthetic groups were then conjugated efficiently to an anti-CD138 monoclonal antibody (75-80% conjugation yield). By using this novel and simple radiohalogenation procedure, higher overall radiochemical yields of astatination were obtained in comparison with the use of an arylstannane precursor and procedures of the litterature for labeling the same antibody. Overall, due to their simplicity of use and high robustness, these new precursors should simplify the labeling of proteins of interest with iodine and astatine radioisotopes for imaging and therapeutic applications.
在本报告中,我们描述了一种基于芳基碘鎓盐前体的用于用放射性碘或砹对抗体进行放射性标记的芳基锡烷化学的替代方法的开发。设计并测试了双功能芳基碘鎓盐用于合成用于生物共轭的碘和砹标记的辅基。改变富电子芳基的性质,并评估其对放射性卤化区域选择性的影响。出乎意料的是,虽然2-噻吩基对目标芳基部分的放射性碘化提供了最佳的区域选择性(98:2),但对砹化的选择性较低(87:13);茴香基提供了最佳的砹化区域选择性(94:6)。在优化条件下,放射性碘化和砹化都可以在温和条件下非常有效地进行(放射化学产率>85%)。利用前体的离子性质开发了一种有效的纯化方法:在传统方法中通常需要的用于优化去除有机锡有毒前体和副产物的HPLC步骤被通过硅胶柱过滤所取代,放射性标记产物的损失显著降低。然后将纯化的放射性碘化和砹化辅基有效地与抗CD138单克隆抗体偶联(偶联产率75-80%)。通过使用这种新颖且简单的放射性卤化程序,与使用芳基锡烷前体和文献中用于标记同一抗体的程序相比,获得了更高的砹化总放射化学产率。总体而言,由于其使用简单且稳健性高,这些新前体应能简化用碘和砹放射性同位素对感兴趣的蛋白质进行标记以用于成像和治疗应用的过程。